Evidence map›Paper›PMID 35532199›Full record

ArticleMolecular genetics & genomic medicine2022

Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: A case study.

Magdalena Cerón-Rodríguez, Daniela Castillo-García, Carlos-Patricio Acosta-Rodríguez-Bueno, Jesús Aguirre-Hernández, Juan-Rafael Murillo-Eliosa, Pedro Valencia-Mayoral, Argelia Escobar-Sánchez, Juan-Luis Salgado-Loza

Open access · goldAbstract readCase Reports
In one paragraph

Article in Molecular genetics & genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Magdalena Cerón-RodríguezDepartment of Lysosomal Diseases, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.ORCID 0000-0002-0330-585X
Daniela Castillo-GarcíaDepartment of Lysosomal Diseases, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Carlos-Patricio Acosta-Rodríguez-BuenoDepartment of Pediatrics, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Jesús Aguirre-HernándezLaboratory of Genomics, Genetics and Bioinformatics, Department of Genetics, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Juan-Rafael Murillo-EliosaDepartment of Pathology, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Pedro Valencia-MayoralDepartment of Pathology, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Argelia Escobar-SánchezDepartment of Pathology, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.
Juan-Luis Salgado-LozaScientific Information Department, SICODIC, Mexico City, Mexico.ORCID 0000-0002-1194-1047
Hospital Infantil de México Federico Gómez · MXUniversidad Intercontinental · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pompe disease (PD) is an autosomal recessive disorder by a deficiency of acid α-glucosidase (GAA) with intralysosomal glycogen accumulation in multiple tissues. We present the case of a 5-month-old male with hypertrophic cardiomyopathy, hypotony, feeding difficulties, and oxygen requirement since birth. At 3 months of age, he develops heart failure, respiratory impairment, and neurological deterioration. The echocardiogram revealed concentric hypertrophic cardiomyopathy with left-diastolic dysfunction. We found increased creatine-phosphokinase, lactate dehydrogenase, and urinary glucose tetrasaccharide levels, 50% of PAS-positive vacuolated lymphocytes in the peripheral blood smear, and low GAA activity. Sequencing of coding exons and flanking intronic sequences revealed a novel homozygous 4 bp deletion in exon 15 of the GAA gene (c.2066_2069delAGCC/p.Glu689Glyfs*6). IOPD was diagnosed. At 5 months old, we started enzyme replacement therapy with an alpha-alglucosidase of 20 mg/kg weekly and immunomodulation with intravenous immunoglobulin. He developed two cardiorespiratory arrests with subsequent neurologic deterioration, convulsive crisis, and respiratory failure and died at 9 months old. We found the usual PD hallmarks in the heart, striated muscle, and liver but also we found neuronal lesions characterized by cytoplasm vacuolization with PAS-positive granules in the central nervous system and myenteric plexus. We describe a novel GAA gene pathogenic variant with a particular phenotype characterized by classic IOPD and neurologic histopathological findings. Enhancing the knowledge of lysosomal diseases is critical to improving the diagnosis and treatment of these patients.

Indexed as

Cardiomyopathy, HypertrophicGlycogen Storage Disease Type IIalpha-GlucosidasesEnzyme Replacement TherapyHumansMaleMuscle, Skeletalalpha-Glucosidasesacid alpha-glucosidasec.2066_2069delAGCCGAA geneinfantile-onset Pompe diseaseneurologicp.Glu689Glyfs*6

Identifiers

PMID35532199
PMCPMC9266604
OpenAlexW4229372425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.